Waning antibody response and cellular immunity 6 months after third dose SARS-Cov-2 mRNA BNT162b2 vaccine in kidney transplant recipients

Am J Transplant. 2022 May;22(5):1498-1500. doi: 10.1111/ajt.16954. Epub 2022 Jan 28.

Authors

Affiliations

¹ Department of Nephrology, Transplantation and hemodialysis, Rouen University Hospital, Rouen, France.
² Department of Virology, Rouen University Hospital, Rouen, France.
³ Department of Immunology and Biotherapies, Rouen University Hospital, Rouen, France.
⁴ INSERM U1234, University of Rouen Normandy, Rouen, France.

No abstract available

Keywords: COVID-19; T cells immunogenicity; kidney transplantation; mRNA vaccine.

Publication types

Letter

MeSH terms

Antibodies, Viral / blood
Antibody Formation*
BNT162 Vaccine* / administration & dosage
BNT162 Vaccine* / immunology
COVID-19* / prevention & control
Humans
Immunity, Cellular*
Immunization, Secondary
Kidney Transplantation*
SARS-CoV-2
Transplant Recipients

Substances

Antibodies, Viral
BNT162 Vaccine